Eyepoint Pharmaceuticals Stock News

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call Transcript

DBV Technologies DBVT +16%. EyePoint Pharmaceuticals (EYPT) +14%. NuCana (NCNA) -54%. MediWound (MDWD) -15%.

EyePoint Pharmaceuticals press release (EYPT): Q4 GAAP EPS of -$0.59 misses by $0.03.Revenue of $11.54M (+61.9% Y/Y) beats by $1.75M.

– Positive EYP-1901 DAVIO Phase 1 eight-month data was presented at Angiogenesis, Exudation, and Degeneration 2022 virtual meeting on February 12, 2022, continuing positive safety and efficacy profile seen at six-month readout

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -18% and 14.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Companies Reporting Before The Bell • Travelzoo (NASDAQ: TZOO ) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban One (NASDAQ: UONEK ) is likely to report earnings for its fourth quarter. • Tile Shop Holdings (NASDAQ: TTSH ) is likely to report earnings for its fourth quarter. • Oxford Square Capital (NASDAQ: OXSQ ) is estimated to report quarterly earnings at $0.09 per share on revenue of $10.30 million. • Aurora Mobile (NASDAQ: JG ) is projected to report quarterly loss at $0.07 per share on revenue of $15.65 million. • Mobile TeleSystems (NYSE: MBT ) is estimated to report quarterly earnings at $0.19 per share on revenue of $1.69 billion. • LENSAR (NASDAQ: LNSR ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.70 million. • Bluegreen Vacations (NYSE: BVH ) is likely to report quarterly earnings at $0.62 per share on revenue of $203.89 million. • Fulcrum Therapeutics (NASDAQ: FULC ) is projected to report quarterly loss at $0.

EyePoint Pharmaceuticals (NASDAQ:EYPT) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open.The consensus EPS Estimate is -$0.51 and the consensus…

WATERTOWN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the live

EyePoint Pharmaceuticals (EYPT) announces eight-month interim data from the DAVIO Phase 1 clinical trial of EYP-1901, for the treatment of wet age-related macular degeneration (wet…

WATERTOWN, Mass., Feb. 12, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients | February 12, 2022

WATERTOWN, Mass., Feb. 12, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced updated interim data from the

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) price on Friday, February 11, rose 1.11% above its previous days close as an upside momentum from buyers pushed the stocks value to $10.00. A look at the stocks price movement, the close in the last trading session was $9.89, moving within a range at $9.48 and $10.19. The beta value EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT) Could Slash -550.0% Soon Read More »

EyePoint Pharmaceuticals Inc (EYPT) shares closed this week 21.3% lower than it did at the end of last week. The stock is currently down 18.9% year-to-date, down 9.1% over the past 12 months, and up 419.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.2%. Trading Activity Shares traded as high as $13.97 and as low as $9.50 this week.Trading volume this week was 31.1% lower than the 10-day average and 7.5% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1053.8% The company's stock price performance over the past 12 months lags the peer average by 2991.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

EyePoint Pharmaceuticals Inc (EYPT) shares closed today 10.6% lower than it did at the end of yesterday. The stock is currently up 15.3% year-to-date, up 36.3% over the past 12 months, and up 646.6% over the past five years. Today, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $14.13 and as low as $11.82 this week.Shares closed 41.3% below its 52-week high and 72.9% above its 52-week low.Trading volume this week was 48.7% lower than the 10-day average and 35.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and beats it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and beats it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 849.4% The company's stock price performance over the past 12 months beats the peer average by -5852.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.